On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth
UCB reported strong financial performance for 2024, with revenue increasing 17% to €6.15 billion and net sales up 15% to €5.61 billion. The growth was driven by newly launched products including BIMZELX®, EVENITY®, FINTEPLA®, RYSTIGGO®, and ZILBRYSQ®, alongside solid contributions from CIMZIA® and BRIVIACT®.
Key regulatory achievements include multiple approvals for BIMZELX® across different indications and regions, including U.S. FDA approvals for psoriatic arthritis, non-radiographic axial spondyloarthritis, ankylosing spondylitis, and hidradenitis suppurativa. The company's adjusted EBITDA reached €1.48 billion, representing 24% of revenue.
For 2025, UCB projects revenue growth to €6.5-6.7 billion, with adjusted EBITDA expected to reach 30% of revenue and Core EPS ranging from €6.80-7.40.
UCB ha riportato una forte performance finanziaria per il 2024, con un aumento del fatturato del 17% a €6,15 miliardi e vendite nette in crescita del 15% a €5,61 miliardi. La crescita è stata sostenuta da nuovi prodotti lanciati, tra cui BIMZELX®, EVENITY®, FINTEPLA®, RYSTIGGO® e ZILBRYSQ®, insieme a solide contribuzioni da CIMZIA® e BRIVIACT®.
Tra i principali risultati normativi ci sono molteplici approvazioni per BIMZELX® in diverse indicazioni e regioni, comprese le approvazioni della FDA statunitense per l'artrite psoriasica, la spondiloartrite assiale non radiografica, la spondilite anchilosante e l'iperidrosi suppurativa. L'EBITDA rettificato dell'azienda ha raggiunto €1,48 miliardi, rappresentando il 24% del fatturato.
Per il 2025, UCB prevede una crescita del fatturato a €6,5-6,7 miliardi, con un EBITDA rettificato che si prevede raggiunga il 30% del fatturato e un utile per azione core compreso tra €6,80 e €7,40.
UCB reportó un sólido desempeño financiero para 2024, con un aumento del 17% en los ingresos, alcanzando los €6.15 mil millones, y un incremento del 15% en las ventas netas, alcanzando los €5.61 mil millones. Este crecimiento fue impulsado por productos recién lanzados, incluyendo BIMZELX®, EVENITY®, FINTEPLA®, RYSTIGGO® y ZILBRYSQ®, junto con contribuciones sólidas de CIMZIA® y BRIVIACT®.
Los logros regulatorios clave incluyen múltiples aprobaciones para BIMZELX® en diferentes indicaciones y regiones, incluidas las aprobaciones de la FDA de EE. UU. para la artritis psoriásica, la espondiloartritis axial no radiográfica, la espondilitis anquilosante y la hidradenitis supurativa. El EBITDA ajustado de la empresa alcanzó los €1.48 mil millones, representando el 24% de los ingresos.
Para 2025, UCB proyecta un crecimiento de los ingresos a €6.5-6.7 mil millones, con un EBITDA ajustado que se espera alcance el 30% de los ingresos y un EPS básico que oscile entre €6.80 y €7.40.
UCB는 2024년 강력한 재무 성과를 보고했으며, 수익이 17% 증가하여 61억 5천만 유로에 달하고 순매출이 15% 증가하여 56억 1천만 유로에 도달했습니다. 이 성장은 BIMZELX®, EVENITY®, FINTEPLA®, RYSTIGGO® 및 ZILBRYSQ®와 같은 신제품의 출시와 CIMZIA® 및 BRIVIACT®의 견고한 기여에 의해 주도되었습니다.
주요 규제 성과로는 다양한 적응증과 지역에서 BIMZELX®에 대한 여러 승인이 포함되며, 여기에는 미국 FDA의 건선 관절염, 비방사선 축성 척추염, 강직성 척추염 및 한선염에 대한 승인이 포함됩니다. 회사의 조정 EBITDA는 14억 8천만 유로에 도달했으며, 이는 수익의 24%를 차지합니다.
2025년을 위해 UCB는 수익이 65억-67억 유로로 성장할 것으로 예상하며, 조정 EBITDA는 수익의 30%에 도달하고 Core EPS는 €6.80-7.40 범위에 있을 것으로 예상하고 있습니다.
UCB a rapporté une solide performance financière pour 2024, avec un chiffre d'affaires en hausse de 17% à 6,15 milliards d'euros et des ventes nettes en hausse de 15% à 5,61 milliards d'euros. Cette croissance a été soutenue par des produits récemment lancés, notamment BIMZELX®, EVENITY®, FINTEPLA®, RYSTIGGO® et ZILBRYSQ®, ainsi que par des contributions solides de CIMZIA® et BRIVIACT®.
Les principales réalisations réglementaires comprennent de multiples approbations pour BIMZELX® dans différentes indications et régions, y compris les approbations de la FDA américaine pour l'arthrite psoriasique, la spondylarthrite axiale non radiographique, la spondylite ankylosante et l'hidradenitis suppurativa. L'EBITDA ajusté de l'entreprise a atteint 1,48 milliard d'euros, représentant 24% du chiffre d'affaires.
Pour 2025, UCB prévoit une croissance du chiffre d'affaires à 6,5-6,7 milliards d'euros, avec un EBITDA ajusté qui devrait atteindre 30% du chiffre d'affaires et un bénéfice par action de base compris entre 6,80 et 7,40 euros.
UCB berichtete über eine starke finanzielle Leistung für 2024, mit einem Umsatzanstieg von 17% auf 6,15 Milliarden Euro und einem Nettoumsatzanstieg von 15% auf 5,61 Milliarden Euro. Das Wachstum wurde durch neu eingeführte Produkte wie BIMZELX®, EVENITY®, FINTEPLA®, RYSTIGGO® und ZILBRYSQ® sowie durch solide Beiträge von CIMZIA® und BRIVIACT® angetrieben.
Zu den wichtigsten regulatorischen Erfolgen gehören mehrere Genehmigungen für BIMZELX® in verschiedenen Indikationen und Regionen, einschließlich der Genehmigungen der US-amerikanischen FDA für psoriatische Arthritis, nicht-radiografische axiale Spondyloarthritis, ankylosierende Spondylitis und Hidradenitis suppurativa. Das bereinigte EBITDA des Unternehmens erreichte 1,48 Milliarden Euro, was 24% des Umsatzes entspricht.
Für 2025 prognostiziert UCB ein Umsatzwachstum auf 6,5-6,7 Milliarden Euro, wobei das bereinigte EBITDA voraussichtlich 30% des Umsatzes erreichen und der Kern-EPS zwischen 6,80 und 7,40 Euro liegen wird.
- Revenue increased 17% to €6.15 billion
- Net sales up 15% to €5.61 billion
- Multiple FDA approvals for BIMZELX across different indications
- BRIVIACT achieved peak sales target ahead of schedule
- Strong patient reach across product portfolio
- CIMZIA patent expiration in U.S. (Feb 2024) and Europe (Oct 2024)
- Failed clinical trials for rozanolixizumab in fibromyalgia
- Minzasolmin failed to meet endpoints in Parkinson's disease study
- Slower than anticipated recruitment for UCB1381 Phase 2a study
- Revenue in 2024 increased to
€ 6.15 billion , a plus of17% (+19% CER1), - Net sales were up by
15% to€ 5.61 billion (+17% CER1) driven by a strong, triple- and double-digit growth performance of newly launched growth drivers: BIMZELX®, EVENITY®, FINTEPLA®, RYSTIGGO® and ZILBRYSQ® as well as solid contribution from CIMZIA® and BRIVIACT® reaching its peak sales two years ahead of target - Underlying profitability (adj. EBITDA2) went up to
€ 1.48 billion , a plus of9% (+18% CER1),24.0% of revenue; Core EPS3 increased to€ 4.98 - R&D update: Doxecitine and doxribtimine in thymidine Kinase 2 deficiency filed in
U.S. – with granted priority review - and in EU; 1st phase 3 with positive results for dapirolizumab pegol in systemic lupus erythematosus (SLE), 2nd phase 3 started; Phase 2a study in atopic dermatitis with UCB9741/galvokimig showed positive and convincing data - Sustainability with significant improvement in patient access, CO2 reduction and ESG ratings
- Financial guidance for 2025: Revenue expected to grow to
€ 6.5 -6.7 billion, adjusted EBITDA2 to reach30% of revenue, Core EPS3 in the range of€ 6.80 -7.40
Jean-Christophe Tellier, CEO UCB says: "Our 2024 performance demonstrates that we are progressing on our path of growth for a decade+ and underlines our unwavering commitment to ensuring people with severe diseases can live the best life that they can, as free as possible from challenges of disease. We are proud to reaching more than 3.1 million patients globally with severe immunological and neurological conditions. As a result of our continuous execution, our five growth drivers tripled their combined net sales to more than
UCB's FY 2024 financial results
€ million | 2024 | 2023 | Act | CER1 |
Revenue | 6 152 | 5 252 | 17 % | 19 % |
Net sales | 5 613 | 4 867 | 15 % | 17 % |
Adj. EBITDA2 | 1 476 | 1 349 | 9 % | 18 % |
Number of shares (m) | 190 | 190 | 0 % | |
Core EPS3 (€) | 4.98 | 4.20 | 19 % | 32 % |
Dividend per share (€) | 1.39 | 1.36 | 2 % | |
Sandrine Dufour, CFO UCB says: "2024 has been a successful year, showcasing UCB's innovation and strong execution capabilities, resulting in robust financial performance and reaching the
Regulatory and Clinical Pipeline Update
UCB continuously innovates and strives to find new ways to deliver solutions to people living with severe immunological and neurological diseases, reflected in a clinical development pipeline encompassing now one phase 4 (post-approval) asset, one asset under regulatory review, four phase 3 projects, four phase 2 projects - addressing different patient populations. The updated timelines for UCB's clinical development program, also reflecting regulatory updates and pipeline progress since July 1, 2024, up to the publication date of this report, are shown below. For more information, please visit https://reports.ucb.com
Regulatory Update
In July 2024, UCB received National Medical Products Administration (NMPA) approval for BIMZELX® for treatment of ankylosing spondylitis (AS) in
In August 2024, the European Commission granted marketing authorization for two 320 mg device presentations of BIMZELX®. The pre-filled syringe and pre-filled pen each contain 320 mg of bimekizumab in a volume of 2 mL and provide alternatives to the currently available 160 mg in a volume of 1 mL injection options.
In September 2024,
In September 2024, the Japanese Ministry of Health, Labor and Welfare (MHLW) approved BIMZELX® for the treatment of adults with moderate to severe hidradenitis suppurativa (HS).
In October 2024, the FDA approved a 2 mL pre-filled syringe and pre-filled autoinjector, each containing 320 mg of BIMZELX®. These new device presentations add to the currently available 1 mL administration options, each containing 160 mg of bimekizumab-bkzx, and mean that patients requiring a 320 mg dose of bimekizumab-bkzx will have options for single-injection administration.
In November 2024, the FDA approved BIMZELX® for the treatment of adults with moderate to severe hidradenitis suppurativa (HS). Bimekizumab-bkzx is the first and only approved medicine designed to selectively inhibit interleukin 17F (IL-17F) in addition to interleukin 17A (IL-17A). The milestone marks the fifth indication for bimekizumab-bkzx in the
In January 2025, the Japanese Ministry of Health, Labor and Welfare (MHLW) approved the 320 mg/2mL Autoinjector for BIMZELX®.
Clinical Pipeline Update
The phase 2a study with rozanolixizumab in severe fibromyalgia syndrome showed statistically significant superiority to placebo but did not meet predefined criteria for progression. The reduction in IgG levels and the safety profile were consistent with what was observed in the myasthenia gravis population. UCB decided not to pursue a Phase 3 program for rozanolixizumab in severe fibromyalgia and to terminate this program.
UCB9741/ galvokimig - a bispecific investigational antibody designed to target IL-13 and IL-17A & IL-17 F, which are key mediators of inflammation. The phase 2a study in moderate-to-severe atopic dermatitis - a type of eczema, which is the most common inflammatory skin disease - showed positive and convincing proof-of-concept data – to be presented at an upcoming scientific meeting in 2025. UCB is evaluating the next steps in the development program.
UCB1381/ donzakimig - a bispecific investigational antibody designed to target IL-13 and IL-22, a key mediator of inflammation and important in maintenance of skin barrier integrity. Recruitment for the Phase 2a study in atopic dermatitis (AtD) is progressing slower than anticipated, leading to an updated timeline with results now expected in the second half of 2025.
Minzasolmin, a phase 2a investigational, oral small molecule, alpha-synuclein misfolding inhibitor, developed in partnership with Novartis for early Parkinson's disease, did not meet its primary and secondary clinical endpoints in the ORCHESTRA proof-of-concept study. No new safety risks were identified, and the program was terminated. The findings from this study have been submitted to an upcoming scientific meeting and will be submitted for publication in a peer-reviewed journal. The data generated to date will enhance understanding of alpha-synuclein misfolding inhibition and aid in the advancement of future treatments.
Bepranemab showed encouraging phase 2a study results in early Alzheimer's disease providing first evidence of biological and clinical effect of a mid-domain tau-targeting disease-modifying therapy. In the full study population, the primary endpoint was not met, however in key secondary endpoints bepranemab showed positive results. In pre-defined patient subgroups, consistent treatment benefit was shown across multiple primary and secondary outcome measures. UCB is evaluating next steps in the development program.
At the end of 2024, regulatory submissions of doxecitine and doxribtimine in thymidine Kinase 2 deficiency (TK2d) occurred as planned and were accepted in February 2025 for review by the European and
Following the acquisition of Zogenix, Inc. in 2022, UCB continued the development of Doxecitine and Doxribtimine, a pyrimidine nucleoside potential therapy for patients with TK2d, a rare, progressive, debilitating and often life-threatening genetic mitochondrial disease characterized by progressive and severe muscle weakness. Worldwide, there is no approved treatment available. UCB expects regulatory feedback and potential approvals by the end of 2025.
The phase 3 study to evaluate the efficacy and safety of bimekizumab in Chinese study participants with moderate to severe plaque psoriasis (PSO) reported positive results. All primary and secondary endpoints were met, and safety observations were generally consistent with previous bimekizumab PSO studies. Submission to the Chinese regulatory authorities is planned for H2 2025.
Recruitment for the phase 3 study with Fenfluramine (5-HT agonist) in the treatment of CDKL5 deficiency disorder (CDD) has required more time than anticipated. CDD is a rare developmental epileptic encephalopathy with onset in early infancy caused by mutations in the CDKL5 gene. The main clinical symptoms are early-onset, intractable epilepsy and neurodevelopmental delay impacting cognitive, motor, speech, and visual function. The study is now fully recruited, and first headline results are expected in H1 2025.
In November 2024, UCB and partner Biogen presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP), a novel Fc-free anti-CD40L drug candidate, demonstrating significant clinical improvement in disease activity in people living with moderate-to-severe systemic lupus erythematosus (SLE). The safety profile of dapirolizumab pegol was generally consistent with previous studies. In December 2024, UCB and Biogen initiated the second Phase 3 trial of dapirolizumab pegol, PHOENYCS FLY, with first headline results expected in 2028.
In September, UCB started BE BOLD, a head-to-head post-approval Phase 4 study, comparing bimekizumab, an IL-17A and IL-17F inhibitor, with risankizumab, an IL-23 inhibitor, in the treatment of adults with active psoriatic arthritis (PsA). BE BOLD is the first head-to-head study in PsA evaluating the superiority of an IL-17A and IL-17F inhibitor to an IL-23 inhibitor. First headline results are expected in H2 2026.
All other clinical studies are continuing as planned.
Sustainability
In 2024, patient access to reimbursement of UCB's medicines improved to
Net sales break-down for UCB's five growth drivers, CIMZIA® and BRIVIACT®
Due to rounding, some financial data may not add up in the tables
BIMZELX® (bimekizumab) the first and only IL-17A & IL-17F inhibitor, is available to people living with psoriasis in 47 countries. It is also available to people living with active psoriatic arthritis (PsA), with active ankylosing spondylitis (AS) in more than 40 countries – the
€ million | 2024 | 2023 | Act | CER1 |
U.S. | 287 | 9 | > | > |
255 | 112 | > | > | |
32 | 16 | > | > | |
International | 33 | 12 | > | > |
Total Bimzelx® | 607 | 148 | > | > |
FINTEPLA® (fenfluramine) reached over 7 600 patients and their families living with seizures associated with rare epileptic syndromes, offering a foundational therapy in Dravet Syndrome and a recognized option in Lennox-Gastaut Syndrome at the end of 2024. Partner Nippon Shinyaku in
€ million | 2024 | 2023 | Act | CER1 |
U.S. | 294 | 201 | 46 % | 46 % |
41 | 21 | 93 % | 92 % | |
2 | 1 | > | > | |
International | 2 | 3 | -16 % | -16 % |
Total Fintepla® | 340 | 226 | 50 % | 50 % |
RYSTIGGO® (rozanolixizumab-noli), a new treatment option for people living with generalized myasthenia gravis (gMG) providing rapid and durable efficacy, was launched in the
€ million | 2024 | 2023 | Act | CER1 |
U.S. | 184 | 19 | > | > |
8 | - | N/A | N/A | |
10 | - | N/A | N/A | |
International | - | - | N/A | N/A |
Total Rystiggo® | 202 | 19 | > | > |
ZILBRYSQ® (zilucoplan) the first and only once-daily subcutaneous, targeted C5 complement inhibitor reached more than 560 people living with myasthenia gravis (gMG) by the end of 2024 and is being launched in the
€ million | 2024 | 2023 | Act | CER1 |
U.S. | 56 | - | N/A | N/A |
8 | - | N/A | N/A | |
8 | - | N/A | N/A | |
International | - | - | N/A | N/A |
Total Zilbrysq® | 72 | - | N/A | N/A |
EVENITY® (romosozumab) since launch globally reached more than 900 000 (2023: 600 000) women living with postmenopausal osteoporosis at high risk of fracture. Net sales in
CIMZIA® (certolizumab pegol) reached more than 220 000 people living with inflammatory TNF mediated diseases. The net sales performance was driven by global volume growth (+
€ million | 2024 | 2023 | Act | CER1 |
U.S. | 1 289 | 1 364 | -5 % | -5 % |
436 | 428 | 2 % | 1 % | |
28 | 39 | -26 % | -20 % | |
International | 280 | 257 | 9 % | 15 % |
Total Cimzia® | 2 033 | 2 087 | -3 % | -2 % |
BRIVIACT® (brivaracetam) was used by over 232 000 people living with epilepsy and increased net sales to
€ million | 2024 | 2023 | Act | CER1 |
U.S. | 540 | 445 | 21 % | 21 % |
120 | 110 | 10 % | 9 % | |
1 | - | N/A | N/A | |
International | 24 | 21 | 14 % | 16 % |
Total Briviact® | 686 | 576 | 19 % | 19 % |
2024 FY financial highlights
Due to rounding, some financial data may not add up in the tables.
Actual1 | Variance | |||
€ million | 2024 | 2023 | Actual rates | CER2 |
Revenue | 6 152 | 5 252 | 17 % | 19 % |
Net sales | 5 613 | 4 867 | 15 % | 17 % |
Royalty income and fees | 78 | 77 | 1 % | 1 % |
Other revenue | 461 | 308 | 50 % | 50 % |
Adjusted Gross Profit | 4 819 | 4 033 | 19 % | 22 % |
Gross Profit | 4 400 | 3 545 | 24 % | 27 % |
Marketing and selling expenses | -2 075 | -1 594 | 30 % | 30 % |
Research and development expenses | -1 781 | -1 630 | 9 % | 9 % |
General and administrative expenses | - 272 | - 230 | 18 % | 18 % |
Other operating income/expenses (-) | 564 | 566 | 0 % | 0 % |
Adjusted EBIT | 836 | 657 | 27 % | 47 % |
Impairment, restructuring and other income/expenses (-) | 488 | - 53 | >- | >- |
EBIT (operating profit) | 1 324 | 604 | > | > |
Net financial expenses (-) | - 161 | - 163 | -1 % | -2 % |
Profit before income taxes | 1 163 | 441 | > | > |
Income tax expenses (-) | - 98 | - 98 | 0 % | 4 % |
Profit from continuing operations | 1 065 | 343 | > | > |
Profit/loss (-) from discontinued operations | 0 | 0 | N/A | N/A |
Profit | 1 065 | 343 | > | > |
Attributable to UCB shareholders | 1 065 | 343 | > | > |
Adjusted EBITDA | 1 476 | 1 349 | 9 % | 18 % |
Capital expenditure (including intangible assets) | 322 | 316 | 2 % | |
Net debt (-) | -1 454 | -2 177 | -33 % | |
Operating cash flow from continuing operations | 1 242 | 761 | 63 % | |
Weighted average number of shares – non diluted (million) | 190 | 190 | 0 % | |
EPS (€ per weighted average number of shares – non diluted) | 5.61 | 1.81 | > | > |
Core EPS (€ per weighted average number of shares – non | 4.98 | 4.20 | 19 % | 32 % |
1 Due to rounding, some financial data may not add up in the tables included in this management report | ||||
"The statutory auditor has issued an unqualified report with no emphasis of matter paragraph dated 26 February 2025 on the company's consolidated accounts as of and for the year ended 31 December 2024 and has confirmed that the accounting data reported in the accompanying press release is consistent, in all material respects, with the accounts from which it has been derived."
Revenue in 2024 increased to
Royalty income and fees were
Gross profit before "amortization of intangible assets linked to sales" was
Gross profit after "amortization of intangible assets linked to sales" reached
Operating expenses increased to
30% higher marketing and selling expenses of€ 2 075 million (+30% CER1) reflecting focused and significant investments behind the global launch activities for UCB's five growth drivers: Global BIMZELX® launch activities in up to five indications, global launch activities for FINTEPLA® in two indications, global RYSTIGGO® and ZILBRYSQ® launch activities for people living with generalized myasthenia gravis (gMG) and the ongoing expansion of EVENITY® inEurope , reaching more and more patients.9% higher research and development expenses of€ 1 781 million (+9% CER1) reflect the continued investments in UCB's innovative R&D pipeline with 10 different study programs encompassing today one phase 4 (post-approval) asset, one asset under regulatory review, four phase 3 projects, four phase 2 projects - addressing ten different patient populations - as well as ongoing earlier research activities. The R&D ratio reached29% in 2024 after31% in 2023 due to strong revenue growth.18% higher general and administrative expenses of€ 272 million (+18% CER) driven by one-time expenses and additional external resources for the new growth organization model implemented at UCB in summer 2024 and by the above-mentioned accounting effect of LTI.- other operating income was stable at
€ 564 million following€ 566 million in 2023 driven by the net contribution of€ 481 million (+31% ) from EVENITY®, compensating a significantly lower other operating income. EVENITY® is being launched successfully globally by Amgen, Astellas and UCB since 2019, with net sales outsideEurope reported by the partners. Hence, the net earnings contribution from outsideEurope is reflected here. In 2023, the sale of a portfolio of established brands inEurope (€ 145 million ) was reported as other operating income. In 2024, two established brands were sold, however reported as other revenue following the IFRS accounting standards.
Underlying operational profitability – adjusted EBITDA2 – increased by
Total impairment, restructuring and other income/expenses was an income of
Net financial expenses reached
Income tax expenses remained stable at
Driven by double-digit revenue growth, higher operating expenses reflecting the strong investments behind the launches and the significant contribution from the gain on disposals, the profit of the Group amounted to
Core earnings per share, adjusted for the after-tax impact of to be adjusted items, the financial one-offs, the after-tax contribution from discontinued operations and the net amortization of intangibles linked to sales, reached
Dividend – the Board of Directors of UCB proposes a dividend of
Financial Guidance 2025 - The year 2025 will be marked by ongoing global launches and in-market performance of the five growth drivers BIMZELX®, RYSTIGGO®, ZILBRYSQ®, FINTEPLA® and EVENITY®, supported by the solid performance of BRIVIACT® and despite expected pricing pressure for CIMZIA®.
For 2025, UCB is aiming for an increase of revenues to the range of
UCB will continue to invest behind launches around the globe to offer potential new solutions for people living with severe diseases and remains committed to invest into research and development advancing its early- and late-stage development pipeline. At the same time, UCB will continue to be cost disciplined and, as in the past, to actively manage the tail of its portfolio. Underlying profitability, adjusted EBITDA, is expected to reach
The figures for the financial guidance 2025 as mentioned above are calculated on the same basis as the actual figures for 2024.
3 Like-for-like includes adjustments to 2024 revenue related to the contribution to topline from divestments (proceeds and net sales) and Minzasolmin termination |
-----------------------
Find the financial reports on UCB website: http://www.ucb.com/investors/Download-center
Today, UCB will host a conference call/video webcast at 08.00 (EST) / 13.00 (GMT) / 14.00 (CET)
Register here: https://www.ucb.com/investors
For further information, contact UCB:
Investor Relations | Global Communications | |
Antje Witte | Sahar Yazdian | Laurent Schots, Media Relations |
Check out our IR App on the App Store and Google Play
About UCB
UCB,
Forward looking statements
This document contains forward-looking statements, including, without limitation, statements containing the words "potential", "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will", "continue" and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results. By their nature, such forward-looking statements are not guaranteeing future performance and are subject to known and unknown risks, uncertainties, and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements contained in this document.
Important factors that could result in such differences include but are not limited to: global spread and impacts of wars, pandemics and terrorism, the general geopolitical environment, climate change, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues, supply chain disruption and business continuity risks; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars or disruptive technologies/business models, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws, and hiring, retention and compliance of its employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline, or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to disputes between the partners or may prove to be not as safe, effective or commercially successful as UCB may have believed at the start of such partnership. UCB's efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also, UCB or others could discover safety, side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB's products that implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB's data and systems.
Given these uncertainties, the public is cautioned not to place any undue reliance on such forward-looking statements. These forward-looking statements are made only as of the date of this document, and do not reflect any potential impacts from the evolving event or risk as mentioned above as well as any other adversity, unless indicated otherwise. The company continues to follow the development diligently to assess the financial significance of these events, as the case may be, to UCB.
UCB expressly disclaims any obligation to update any forward-looking statements in this document, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable
laws and regulations.
1 CER = constant exchange rates |
View original content to download multimedia:https://www.prnewswire.com/news-releases/on-growth-path-for-a-decade-plus-strong-launch-execution-driving-company-growth-302386784.html
SOURCE UCB
FAQ
What were UCB's (UCBJY) key financial metrics for 2024?
What new FDA approvals did BIMZELX receive in 2024?
What is UCB's financial guidance for 2025?
How many patients did UCB's growth drivers reach in 2024?
